ERBB2 and breast cancer: Interestingly, higher expression of these macrophage markers was associated with worse outcomes of ER+, HER2+, TNBC, and all subtypes, respectively (Fig. S5C, D), suggesting that these four subsets might be indicators of worse prognosis in their respective breast cancer patients.